{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T13:57:16Z","timestamp":1781013436079,"version":"3.54.1"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"37","license":[{"start":{"date-parts":[[2022,6,25]],"date-time":"2022-06-25T00:00:00Z","timestamp":1656115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>It is unknown whether Asian and non-Asian patients with atherosclerotic vascular disease derive similar benefits from long-term antithrombotic therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>In patients with chronic coronary artery disease (CAD) and\/or peripheral artery disease (PAD) enrolled in The Cardiovascular Outcomes for People Using Anticoagulation Strategies trial, the effects of rivaroxaban 2.5\u2005mg b.i.d. plus aspirin 100\u2005mg o.d. were compared with those of aspirin 100\u2005mg o.d. in Asian vs. non-Asian patients (race was self-identified). Asians (n\u2009=\u20094269) vs. non-Asians (n\u2009=\u200923\u2009126) had similar rates of major adverse cardiovascular events (MACEs) (4.85% vs. 4.83%, P\u2009=\u20090.30) and modified International Society on Thrombosis and Haemostasis (ISTH) major bleeding (2.72% vs. 2.58%, P\u2009=\u20090.22), but higher rates of intracranial haemorrhage (ICH) (0.63% vs. 0.29%, P\u2009=\u20090.01) and minor bleeding (13.61% vs. 6.49%, P\u2009&amp;lt;\u20090.001). In Asians vs. non-Asians, the combination of rivaroxaban and aspirin compared with aspirin alone produced consistent reductions in MACE [Asians: hazard ratio (HR): 0.64, 95% confidence interval (CI): 0.45\u20130.90; non-Asians: HR: 0.78, 95% CI: 0.67\u20130.90; P(heterogeneity)\u2009=\u20090.29], increases in modified ISTH major bleeding (Asians: HR 2.24, 95% CI: 1.40\u20133.58; non-Asians: HR: 1.60, 95% CI: 1.30\u20131.97; P\u2009=\u20090.20), and net clinical outcome (Asians: HR: 0.77, 95% CI: 0.56\u20131.05; non-Asians: HR: 0.81, 95% CI: 0.70\u20130.93, P\u2009=\u20090.78), but borderline higher rates of ICH (Asians: HR: 3.50, 95% CI: 0.98\u201312.56; non-Asians: HR: 0.81, 95% CI: 0.43, 1.53; P\u2009=\u20090.04).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Asian compared with non-Asian patients with chronic CAD and\/or PAD have higher rates of ICH and minor bleeding. The combination of rivaroxaban and aspirin vs. aspirin alone produces similar effects for MACE, modified ISTH major bleeding, and net clinical outcome but may be associated with higher rates of ICH in Asian patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehac309","type":"journal-article","created":{"date-parts":[[2022,6,25]],"date-time":"2022-06-25T09:51:11Z","timestamp":1656150671000},"page":"3542-3552","source":"Crossref","is-referenced-by-count":16,"title":["Rivaroxaban and aspirin vs. aspirin alone in Asian compared with non-Asian patients with chronic coronary artery disease or peripheral arterial disease: the COMPASS trial"],"prefix":"10.1093","volume":"43","author":[{"given":"Masatsugu","family":"Hori","sequence":"first","affiliation":[{"name":"Osaka International Cancer Institute , Osaka , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4309-5789","authenticated-orcid":false,"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[{"name":"FuWai Hospital , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Liang","sequence":"additional","affiliation":[{"name":"FuWai Hospital , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0487-7531","authenticated-orcid":false,"given":"Deepak L","family":"Bhatt","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Harvard Medical School , MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6292-4207","authenticated-orcid":false,"given":"Jackie","family":"Bosch","sequence":"additional","affiliation":[{"name":"McMaster University , Hamilton, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart J","family":"Connolly","sequence":"additional","affiliation":[{"name":"McMaster University , Hamilton, Ontario , Canada"},{"name":"Population Health Research Institute , Hamilton, Ontario , Canada"},{"name":"Hamilton Health Sciences Hamilton , Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith A A","family":"Fox","sequence":"additional","affiliation":[{"name":"Centre for Cardiovascular Science, University of Edinburgh , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo","family":"Maggioni","sequence":"additional","affiliation":[{"name":"ANMCO Research Center , Florence , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim","family":"Yusuf","sequence":"additional","affiliation":[{"name":"McMaster University , Hamilton, Ontario , Canada"},{"name":"Population Health Research Institute , Hamilton, Ontario , Canada"},{"name":"Hamilton Health Sciences Hamilton , Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4126-1285","authenticated-orcid":false,"given":"John W","family":"Eikelboom","sequence":"additional","affiliation":[{"name":"McMaster University , Hamilton, Ontario , Canada"},{"name":"Population Health Research Institute , Hamilton, Ontario , Canada"},{"name":"Hamilton Health Sciences Hamilton , Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,6,25]]},"reference":[{"key":"2022100812132618800_ehac309-B1","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.chest.2019.04.108","article-title":"Effectiveness and safety of four direct oral anticoagulants in Asian patients with nonvalvular atrial fibrillation","volume":"156","author":"Chan","year":"2019","journal-title":"Chest"},{"key":"2022100812132618800_ehac309-B2","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1007\/s11739-021-02672-5","article-title":"Safety of antithrombotic therapy in east Asian patients","volume":"16","author":"Goto","year":"2021","journal-title":"Intern Emerg Med"},{"key":"2022100812132618800_ehac309-B3","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ijcard.2014.11.182","article-title":"Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in Asian patients with atrial fibrillation: time for a reappraisal","volume":"180","author":"Lip","year":"2015","journal-title":"Int J Cardiol"},{"key":"2022100812132618800_ehac309-B4","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1161\/STROKEAHA.115.009947","article-title":"Non-vitamin K antagonist oral anticoagulants for stroke prevention in Asian patients with nonvalvular atrial fibrillation: meta-analysis","volume":"46","author":"Wang","year":"2015","journal-title":"Stroke"},{"key":"2022100812132618800_ehac309-B5","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"key":"2022100812132618800_ehac309-B6","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jacc.2021.04.083","article-title":"Mortality benefit of rivaroxaban plus aspirin in patients with chronic coronary or peripheral artery disease","volume":"78","author":"Eikelboom","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2022100812132618800_ehac309-B7","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0140-6736(17)32458-3","article-title":"Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial","volume":"391","author":"Connolly","year":"2018","journal-title":"Lancet"},{"key":"2022100812132618800_ehac309-B8","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0140-6736(17)32409-1","article-title":"Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial","volume":"391","author":"Anand","year":"2018","journal-title":"Lancet"},{"key":"2022100812132618800_ehac309-B9","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.cjca.2017.06.001","article-title":"Rationale, design and baseline characteristics of participants in the cardiovascular outcomes for people using anticoagulation strategies (COMPASS) trial","volume":"33","author":"Bosch","year":"2017","journal-title":"Can J Cardiol"},{"key":"2022100812132618800_ehac309-B10","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1016\/j.jacc.2019.03.479","article-title":"Monitoring emerging data from the COMPASS trial of an antithrombotic agent","volume":"73","author":"Cairns","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2022100812132618800_ehac309-B11","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1055\/s-0040-1718729","article-title":"The east Asian paradox: an updated position statement on the challenges to the current antithrombotic strategy in patients with cardiovascular disease","volume":"121","author":"Kim","year":"2021","journal-title":"Thromb Haemost"},{"key":"2022100812132618800_ehac309-B12","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.ahj.2008.08.031","article-title":"Ethnic variation in adverse cardiovascular outcomes and bleeding complications in the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance (CHARISMA) study","volume":"157","author":"Mak","year":"2009","journal-title":"Am Heart J"},{"key":"2022100812132618800_ehac309-B13","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1161\/STROKEAHA.113.000990","article-title":"Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in asians and non-asians with atrial fibrillation","volume":"44","author":"Hori","year":"2013","journal-title":"Stroke"},{"key":"2022100812132618800_ehac309-B14","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1253\/circj.CJ-12-0454","article-title":"J-ROCKET AF study investigators. Rivaroxaban vs warfarin in Japanese patients with atrial fibrillations \u2013 the J-ROCKET AF study","volume":"76","author":"Hori","year":"2012","journal-title":"Circ J"},{"key":"2022100812132618800_ehac309-B15","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1056\/NEJMoa2012883","article-title":"Low-dose edoxaban in very elderly patients with atrial fibrillation","volume":"383","author":"Okumura","year":"2020","journal-title":"N Engl J Med"},{"key":"2022100812132618800_ehac309-B16","first-page":"407","article-title":"ESC Guidelines for the diagnosis and management of chronic coronary syndromes","volume":"2020","author":"Knuuti","year":"2019","journal-title":"Eur Heart J"},{"key":"2022100812132618800_ehac309-B17","first-page":"763","article-title":"ESC Guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European society for vascular surgery (ESVS): document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Endorsed by: the European stroke organization (ESO)The task force for the diagnosis and treatment of peripheral arterial diseases of the European society of cardiology (ESC) and of the European society for vascular surgery (ESVS)","volume":"2018","author":"Aboyans","year":"2017","journal-title":"Eur Heart J"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/43\/37\/3542\/46383494\/ehac309.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/43\/37\/3542\/46383494\/ehac309.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T12:18:35Z","timestamp":1665231515000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/43\/37\/3542\/6617778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,25]]},"references-count":17,"journal-issue":{"issue":"37","published-online":{"date-parts":[[2022,6,25]]},"published-print":{"date-parts":[[2022,10,7]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehac309","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,10,7]]},"published":{"date-parts":[[2022,6,25]]}}}